Key Highlights
- Harrow, Inc. (NASDAQ: HROW) announced a second-quarter Revenue of $70.7 million, up 60% sequentially but reporting an EPS of $-0.34, below the consensus estimate of $-0.18.
- Quarterly revenue of $70.7 million marked an 11% increase year-over-year, bolstered by VEVYE's strong performance and IHEEZO’s record demand, which surged 44% sequentially.
- The company reiterated its full-year revenue guidance of $350 million to $365 million, suggesting confidence in future performance driven by product launches and recent acquisitions, notably TYRVAYA.
Harrow, Inc. (NASDAQ: HROW) announced a second-quarter revenue of $70.7 million, up 60% sequentially but reporting an EPS of $-0.34, below the consensus estimate of $-0.18. This performance highlights ongoing challenges, as shares have dropped 18.5% year-to-date, indicating investor caution despite significant revenue growth.
What Happened
Harrow's second-quarter results reflected a substantial increase in revenue, primarily driven by product sales, with VEVYE generating $29.4 million, a sequential gain of approximately 40% and nearly 58% year-over-year. Despite this growth, the company did not meet Earnings expectations, reporting an EPS of $-0.34 compared to the consensus forecast of $-0.18. The revenue increase aligns with the company's expanded commercial approach and strategic initiatives, particularly in the ophthalmic market.
However, missed earnings may lead to investor concern regarding operational efficiency and overall profitability.
Revenue Drivers
Quarterly revenue of $70.7 million marked an 11% increase year-over-year, bolstered by VEVYE's strong performance and IHEEZO’s record demand, which surged 44% sequentially. Harrow also secured expanded formulary coverage for VEVYE on August 1, potentially improving patient access and aligning with the company's strategy to penetrate the dry eye therapy market further. Despite these advances, the adjusted EBITDA remains in the negative at $-1.23 million, indicating ongoing Investment in scaling operations.
The contrasting metrics point to a need for sustained execution as the company seeks to balance growth with profitability.
Why Now / What It Signals
The company reiterated its full-year revenue guidance of $350 million to $365 million, suggesting confidence in future performance driven by product launches and recent acquisitions, notably TYRVAYA. VEVYE’s recent formulary win and IHEEZO’s continued Demand growth position Harrow well in the competitive environment of ophthalmic treatments. As peers like XERS and AVLN showed mixed performance today, the company’s strategic focus on expanding the product portfolio could help it regain investor favor.
What to Watch Next
Harrow will host a conference call on August 11 to discuss its latest results, which may provide additional insights into management's strategy going forward. This call could shed light on the operational adjustments necessary to improve profitability and drive revenue growth, particularly amid the evolving competitive dynamics in the ophthalmic market. The anticipated Acquisition of TYRVAYA is also expected to play a significant role in strengthening Harrow's market position in the second half of 2026, making the upcoming discussions critical for stakeholder assessment.
Peers Moving on This News
- Innoviva Inc (INVA) little changed
- Xeris Biopharma Holdings Inc (XERS) down 1.1%
- Avalyn Pharma Inc (AVLN) up 1.3%
Analysis based on the Form 8-K filed 10 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...